Sino Partners provides dual-jurisdiction regulatory advisory for Chinese businesses entering Oceania and Oceania businesses engaging China - bridging TGA/NMPA, ACQSC/MHAC, EPA/MEE and FIRB/NDRC regulatory frameworks in a single integrated service.
For Chinese businesses entering Oceania's health, aged care, waste and infrastructure sectors, regulatory compliance is not a final step - it is the foundation on which every commercial decision must be built. Misunderstanding Australian or New Zealand regulatory requirements is the single most common - and most expensive - cause of market entry failure.
Sino Partners provides end-to-end regulatory bridging advisory, combining deep knowledge of Chinese regulatory frameworks (NMPA, MOFCOM, NDRC, MEE) with expert understanding of Oceania's sector-specific regulatory environments across health, aged care, environment and infrastructure.
Every China-Oceania engagement involves at least two regulatory environments. We know both sides deeply.
Specialist dual-jurisdiction regulatory advisory across Oceania's most complex sectors for Chinese market entrants.
Sino Partners provides complete regulatory pathway advisory for Chinese medical device, therapeutic goods and diagnostic product manufacturers seeking TGA (Australia) or Medsafe (New Zealand) registration.
We map your product to the correct regulatory pathway, prepare the evidence dossier, manage the submission process and provide ongoing compliance advisory after registration.
Operating in Australia's aged care sector requires ongoing compliance with the Aged Care Quality Standards, the Support at Home program requirements and ACQSC audit processes. For Chinese technology and service businesses entering this sector, establishing compliance from the outset is critical.
Chinese businesses in waste processing, recycling and infrastructure sectors face complex environmental regulatory requirements across Australian state EPAs and federal environment laws, as well as Chinese MEE obligations for cross-border environmental impacts.
Cross-border investment between China and Oceania requires simultaneous navigation of Australian FIRB screening and Chinese NDRC/MOFCOM outbound investment approval processes. Sino Partners manages both sides of this process in a single coordinated engagement.
Australia's digital health regulatory environment is evolving rapidly, with the Australian Digital Health Agency, Privacy Act and My Health Record system creating specific compliance obligations for Chinese digital health technology businesses.
Map your product, technology or service to the correct regulatory pathways in both China and Oceania, identifying requirements and timelines.
Prepare the technical, clinical and commercial evidence required for regulatory submissions in both jurisdictions.
Manage the full submission process, liaising directly with regulatory bodies on your behalf in both Mandarin and English.
Provide ongoing compliance advisory as regulations evolve and your product or service offering develops over time.
We know both sides - Chinese regulatory frameworks and Oceania regulatory requirements - in depth. No other firm in the market offers this combination.
Regulatory submissions managed in Mandarin for Chinese bodies and English for Oceania authorities - with full accuracy and no translation risk.
We do not offer generic regulatory advisory. Every engagement is grounded in the specific requirements of your sector and product class.
Established relationships with regulatory consultants, legal advisors and former regulatory agency staff in both China and Oceania.
We compress regulatory timelines through thorough pre-submission preparation and proactive liaison with regulators.
Our regulatory advisory is always connected to the broader commercial strategy - we ensure compliance accelerates your market entry rather than delaying it.
Contact our regulatory bridging team to map your pathway to compliance in Australia, New Zealand and China.
Start a Conversation →